References

1. Grimer RJ, Athanasou N, Gerrand C, Judson I, Lewis I, Morland B, et al. UK guidelines for the management of bone sarcomas. Sarcoma 2008;317462.doi: 10.1155/2010/317462.

2. The European Sarcoma Network Working Group. Bone Sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(suppl7):vii100vii109.

3. NCCN [Internet]. Pennsylvania: National Comprehensive Cancer Network. NCCN guidelines for bone cancer. Version 1.2014; c2014 [updated 2014] Available fromhttp://www.nccn.org/

4. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, et al. Soft tissue sarcoma, version 2.2014. J Natl Compr Canc Netw 2014;12(4):47383.

5. The European Sarcoma Network Working Group. Soft Tissue and Visceral Sarcomas: EMSO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(suppl8):vii92vii99.

6. Grimer R, Judson I, Peake D, Seddon B. Guidelines for the management of soft tissue sarcomas. Sarcoma 2010;506182. doi: 10.1155/2010/506182.

7. King DM, Hackbarth DA, Kilian CM, Carrera GF. Soft tissue sarcoma metastases identified on abdomen and pelvis CT imaging. Clin Orthop Relat Res 2009;467(11):283844.doi:10.1007/s11999-009-0989-1

8. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU 3rd, et al. Use of position emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103(2):33948.

9. Eisenhauer EA, Therasse P, Bogaerts J, Schwatz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline. (version 1.1). Eur J Cancer 2009;45(2):22847.

10. Omura MC, Motamedi K, Uybicos S, Nelson SD, Seeger LL. Revisiting CT-guided percutaneous core needle biopsy of musculoskeletal lesions: contributors to biopsy success. AJR Am Roentgenol 2011;197(2):45761.

11.Hogendoorn PC, ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, Dei Tos AP, et al. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol 2010;21(suppl5):v20413

12. Grimer RJ, Briggs TW. Earlier diagnosis of bone and soft tissue tumours. J Bone Joint Surg Br 2010;92(11):148992.

13. Sung KS, Seo SW, Shon MS. The diagnostic value of needle biopsy for musculoskeletal lesions. Int Orthop 2009;33(60):17016.

14. Ashford RU, McCarthy SW, Scolyer RA, Bonar SF, Karim RZ, Stalley PD. Surgical biopsy with intra-operative frozen section. An accurate and cost-effective method for diagnosis of musculoskeletal sarcomas. J Bone Joint Surg Br 2006;88(9):120711.

15. Grimer RJ, Sneath RS. Diagnosing malignant bone tumours. J Bone Joint Surg Br 1990;72(5):7546.

16. Enneking WF. The issue of biopsy. J Bone Joint Surg Am 1982;64:111920.

17. Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft tissue tumours. J Bone Joint Surg Am 1982;64(8):11217.

18. Cap [Internet]. Illinois: College of American Pathologists; c19962003 [updated 2013 June 19; cited 2014 July 3]. Available fromhttp://www.cap.org/apps/cap.portal

19. The Royal College of Pathologists [Internet]. London: The Royal College of Pathologists; c2014. Available fromwww.rcpath.org

20. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (Eds.). WHO classification of tumours of soft tissue and bone. IARC Press: Lyon, 2013.

21. RCPA [Internet]. Australia: The Royal College of Pathologists of Australasia; c2014 [updated 2013 December 16]. Available fromwww.rcpa.edu.au

22.Dujardin F, Binh MB, Bouvier C, Gomez-Brouchet A, Larousserie F, Muret Ad, et al. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol 2011;24(5):62437.doi: 10.1038/modpathol.2010.229.

23. Oliveira AM, Perez-Atayde AP, Inwards CY, Medeiros F, Derr V, His BL, et al. USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol 2004;165(5):177380.

24. Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005;23(3):55968.

25. Bielack SS, Kempf-Bielack B, Branscheid D, Carrle D, Friedel G, Helmke K, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment and outcomes of 249 consecutive Cooperative Osteosarcoma Study Group patients. J Clin Oncol 2008;27(4):55765.

26. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. New Eng J Med 1986;314(25):16006.

27. Eliber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987;5:216.

28. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20(3):77690.

29. Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, et al. Randomised trial of two regiments of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997;350(9082):9117.

30. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survivala report from the Childrens Oncology Group. J Clin Oncol 2008;26(4):6338.doi: 10.1200/JCO.2008.14.0095

31. Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Childrens Oncology Group. Cancer 2009;115(22):533948.doi: 10.1002/cncr.24566

32. Baldini ZH, Goldberg J, Jenner C, Malona JB, Demetri GD, Fletcher CDM, et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol 1999;17(10):32529.

33. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16(1):197203.

34. Fein DA, Lee WR, Lanciano RM, Corn BW, Herbert SH, Hanlon AL, et al. Management of extremity soft tissue sarcomas with limb-sparing surgery and post-operative irradiation: do total dose, overall treatment time, and the surgery-radiotherapy impact on local control? Int J Radiat Oncol Biol Phys 1995;32(4):96976.

35. Mundt AJ, Awan A, Sibley GS, Simon M, Rubin SJ, Samuels B, et al. Conservative surgery and adjuvant radiation therapy in the management of adult soft tissue sarcoma of the extremities: clinical and radiobiological results. Int J Radiat Oncol Biol Phys 1995;32(4):97785.

36. OSullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Pre-operative versus post-operative radiotherapy in soft tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359(9325):223541.

37. Kattan MW, Leung DH, Brennan MF. Post-operative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002;20(3):7916.

38. Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M, et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 2005;103(2):4028.

39. Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt-Koops H, Buesa J, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcomareduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994;12(6):113749.

40. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft tissue sarcoma. Cancer 2008;113(3):57381.

41. Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012;13(10):104554.

42. Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol 2012;30(8):8506.

43. Clinical Trials.gov [Internet] Maryland: U.S National Institutes of Health; Available fromhttp://clinicaltrials.gov/ct2/show/NCT01710176

44. Judson I, Verweij J, Gelderblom H, Hartmann JT,Schffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014;15(4):41523.

45. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007;25(19):275563.

46.Garca-Del-Muro X,Lpez-Pousa A,Maurel J,Martn J,Martnez-Trufero J,Casado A, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011;29(18):252833.

47. Pautier P, Floquet A, Penel N, Piperno-Neumann S, Isambert N, Rey A, et al. Randomized multicentre and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist 2012;17(9):121320.

48. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al.Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet 2012;379(9829):187986.

49.Grosso F,Jones RL,Demetri GD,Judson IR,Blay JY,Le Cesne A, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8(7):595602.

50.Penel N,Bui BN,Bay JO,Cupissol D,Ray-Coquard I,Piperno-Neumann S, et al.Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.Clin Oncol2008;26(32):526974.